Joshua Free delivers remarks to Senate Health Care Committee regarding history, intent, and misconceptions about the 340B drug pricing program on 9/23/2024.
From the hearing:
"340B is one way that safety net providers stay afloat. Some argue that we shouldn’t rely on 340B to do that. Greater amounts of direct funding would surely be welcome, but that does nothing to address the wildly out of control drug prices that actually cause growth in 340B discounts in the first place. If drug makers want to limit their exposure to 340B, they can simply stop pricing drugs in a way that causes 340B to grow."
Comments